Immix Biopharma, Inc. (IMMX) announced that it has achieved a complete response rate CR of 95% in the interim data of the NEXICART-2 trial evaluating NXC-201 in the treatment of relapsed/refractory AL Amyloidosis.
Following the news, IMMX is up 8.95% in the pre-market to $9.74.
AL amyloidosis is a devastating immune condition that produces toxic light chains that accumulate in the heart, kidneys, and liver, leading to organ failure and death.
Trial Details
NEXICART-2 is a multi-site U.S. Phase 2 clinical trial of sterically optimised CAR-T NXC-201 in relapsed/refractory AL Amyloidosis involving 45 patients.
NXC-201
NXC-201 is designed as a sterically optimised BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy to help the immune system recognise and eliminate the source of toxic light chains in treating relapsed/refractory AL Amyloidosis.
Key Findings
Of the first 20 patients, all four MRD-negative patients have converted to a complete response.
CR rate is now 95%, with 19 out of 20 patients achieving CR, and CRs were achieved within 1 year of follow-up.
In addition, no relapses were observed among patients who had reached a complete response, according to the firm.
What's Ahead?
The firm expects to share the next NEXICART2 update in September, 2026.
These results support the firm's plan to initiate a multi-centre, randomised Phase 3 trial in patients with newly diagnosed AL Amyloidosis.
The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research as of 2023.
IMMX has traded between $1.87 and $11.61 over the last year. The stock closed on Wednesday's market at $8.94, up 0.90%.
For more such news For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.